Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Dietrich, Jes ^a   Andreasen, Lars Vibe ^a   Andersen, Peter ^a   Agger, Else Marie ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CAF01; GAMMA INTERFERON; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G2C; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSE SPARING; DRUG DOSAGE FORM COMPARISON; DRUG DOSE; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; INTESTINE; MOUSE; NONHUMAN; POLIOMYELITIS VIRUS; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLISM; SERODIAGNOSIS; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; IMMUNITY, CELLULAR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; INTESTINES; MICE, INBRED C57BL; NEUTRALIZATION TESTS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; VACCINATION;

EID: 84903532428     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100879     Document Type: Article

References (63)

1. Estivariz CF, Pallansch MA, Anand A, Wassilak SG, Sutter RW, et al. (2013) Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol 3: 309-315.
2. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA (2005) Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 59: 587-635. (Pubitemid 41507443)
3. Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Mwanza M, et al. (2010) Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med 362: 2360-2369.
4. Mateen FJ, Shinohara RT, Sutter RW (2013) Oral and inactivated poliovirus vaccines in the newborn: a review. Vaccine 31: 2517-2524.
5. Henry JL, Jaikaran ES, Davies JR, Tomlinson AJ, Mason PJ, et al. (1966) A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J Hyg 64: 105-120.
6. Marine WM, Chin TD, Gravelle CR (1962) Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. Am J Hyg 76: 173-195.
7. Cuba IPVSCG (2007) Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med 356: 1536-1544.
8. Okayasu H, Sutter RW, Czerkinsky C, Ogra PL (2011) Mucosal immunity and poliovirus vaccines: impact on wild poliovirus infection and transmission. Vaccine 29: 8205-8214.
9. Hawken J, Troy SB (2012) Adjuvants and inactivated polio vaccine: a systematic review. Vaccine 30: 6971-6979.
10. Brady RC, Treanor JJ, Atmar RL, Keitel WA, Edelman R, et al. (2009) Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 27: 5091-5095.
11. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354: 1343-1351.
12. Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, et al. (2010) Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 28: 840-848.
13. Baras B, Bouveret N, Devaster JM, Fries L, Gillard P, et al. (2008) A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses. Influenza Other Respir Viruses 2: 251-260.
14. Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, et al. (2010) Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 28: 849-857.
15. Westdijk J, Koedam P, Barro M, Steil BP, Collin N, et al. (2013) Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains. Vaccine 31: 1298-1304.
16. Yang C, Shi H, Zhou J, Liang Y, Xu H (2009) CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus. Vaccine 27: 6558-6563.
17. Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, et al. (2008) Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 3: e3116.
18. Olsen AW, Theisen M, Christensen D, Follmann F, Andersen P (2010) Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model. PLoS One 5: e10768.
19. Rosenkrands I, Vingsbo-Lundberg C, Bundgaard TJ, Lindenstrom T, Enouf V, et al. (2011) Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes. Vaccine 29: 6283-6291.
20. Roman VR, Jensen KJ, Jensen SS, Leo-Hansen C, Jespersen S, et al. (2013) Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau. AIDS Res Hum Retroviruses 29: 1504-1512.
21. Karlsson I, Brandt L, Vinner L, Kromann I, Andreasen LV, et al. (2013) Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection. Clin Immunol 146: 120-130.
22. Fomsgaard A, Karlsson I, Gram G, Schou C, Tang S, et al. (2011) Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. Vaccine 29: 7067-7074.
23. Martel CJM, Agger EM, Poulsen JJ, Jensen TH, Andresen L, et al. (2011) CAF01 Potentiates Immune Responses and Efficacy of an Inactivated Influenza Vaccine in Ferrets. PLoS One 6.
24. Holmgren J, Svennerholm AM (2012) Vaccines against mucosal infections. Curr Opin Immunol 24: 343-353.
25. Ranasinghe C (2014) New advances in mucosal vaccination. Immunol Lett.
26. Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11: S45-53. (Pubitemid 40562303)
27. Yoshino N, Kanekiyo M, Hagiwara Y, Okamura T, Someya K, et al. (2010) Intradermal delivery of recombinant vaccinia virus vector DIs induces gutmucosal immunity. Scand J Immunol 72: 98-105.
28. Enioutina EY, Visic D, Daynes RA (2000) The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine 18: 2753-2767. (Pubitemid 30211584)
29. Zehrung D, Jarrahian C, Wales A (2013) Intradermal delivery for vaccine dose sparing: overview of current issues. Vaccine 31: 3392-3395.
30. Hickling JK, Jones KR, Friede M, Zehrung D, Chen D, et al. (2011) Intradermal delivery of vaccines: potential benefits and current challenges. Bull World Health Organ 89: 221-226.
31. Billeskov R, Elvang TT, Andersen PL, Dietrich J (2012) The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS One 7: e39909.
32. Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, et al. (2005) Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 1718: 22-31. (Pubitemid 41698893)
33. Chen J, Lau YF, Lamirande EW, Paddock CD, Bartlett JH, et al. (2010) Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol 84: 1289-1301.
34. Yin L, Calvo-Calle JM, Cruz J, Newman FK, Frey SE, et al. (2013) CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans. J Immunol 190: 6023-6033.
35. Sette A, Moutaftsi M, Moyron-Quiroz J, McCausland MM, Davies DH, et al. (2008) Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 28: 847-858. (Pubitemid 351778408)
36. Liu T, Chambers TJ (2001) Yellow fever virus encephalitis: properties of the brain-associated T-cell response during virus clearance in normal and gamma interferon-deficient mice and requirement for CD4+ lymphocytes. J Virol 75: 2107-2118. (Pubitemid 32147550)
37. Thomsen AR, Nansen A, Andersen C, Johansen J, Marker O, et al. (1997) Cooperation of B cells and T cells is required for survival of mice infected with vesicular stomatitis virus. Int Immunol 9: 1757-1766. (Pubitemid 27494138)
38. Scherle PA, Gerhard W (1986) Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin. J Exp Med 164: 1114-1128. (Pubitemid 16031610)
39. Milich DR, McLachlan A, Thornton GB, Hughes JL (1987) Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature 329: 547-549. (Pubitemid 17124776)
40. Mahon BP, Katrak K, Nomoto A, Macadam AJ, Minor PD, et al. (1995) Poliovirus-specific CD4+ Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor. J Exp Med 181: 1285-1292.
41. Katrak K, Mahon BP, Minor PD, Mills KH (1991) Cellular and humoral immune responses to poliovirus in mice: a role for helper T cells in heterotypic immunity to poliovirus. J Gen Virol 72 (Pt 5): 1093-1098.
42. Buisman AM, Abbink F, Schepp RM, Sonsma JA, Herremans T, et al. (2008) Preexisting poliovirus-specific IgA in the circulation correlates with protection against virus excretion in the elderly. J Infect Dis 197: 698-706. (Pubitemid 351364470)
43. Baldwin SL, Fox CB, Pallansch MA, Coler RN, Reed SG, et al. (2011) Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine 29: 644-649.
44. Ivanov AP, Dragunsky EM, Chumakov KM (2006) 1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. J Infect Dis 193: 598-600. (Pubitemid 43202752)
45. Estivariz CF, Jafari H, Sutter RW, John TJ, Jain V, et al. (2012) Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis 12: 128-135.
46. Modlin JF (2012) Inactivated polio vaccine and global polio eradication. Lancet Infect Dis 12: 93-94.
47. Dagan R, Amir J, Mijalovsky A, Kalmanovitch I, Bar-Yochai A, et al. (2000) Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J 19: 1045-1052.
48. Fiore AE, Shapiro CN, Sabin K, Labonte K, Darling K, et al. (2003) Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr Infect Dis J 22: 354-359. (Pubitemid 36461039)
49. Klinkenberg D, Moormann RJ, de Smit AJ, Bouma A, de Jong MC (2002) Influence of maternal antibodies on efficacy of a subunit vaccine: transmission of classical swine fever virus between pigs vaccinated at 2 weeks of age. Vaccine 20: 3005-3013. (Pubitemid 34785972)
50. Loeffen WL, Heinen PP, Bianchi AT, Hunneman WA, Verheijden JH (2003) Effect of maternally derived antibodies on the clinical signs and immune response in pigs after primary and secondary infection with an influenza H1N1 virus. Vet Immunol Immunopathol 92: 23-35. (Pubitemid 36298680)
51. Nahm MH, Glezen P, Englund J (2003) The influence of maternal immunization on light chain response to Haemophilus influenzae type b vaccine. Vaccine 21: 3393-3397. (Pubitemid 36792093)
52. Weeratna RD, Brazolot Millan CL, McCluskie MJ, Siegrist CA, Davis HL (2001) Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies. FEMS Immunol Med Microbiol 30: 241-247. (Pubitemid 32373300)
53. Siegrist CA, Barrios C, Martinez X, Brandt C, Berney M, et al. (1998) Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Eur J Immunol 28: 4138-4148. (Pubitemid 28558644)
54. Krishnan R, Jadhav M, John TJ (1983) Efficacy of inactivated poliovirus vaccine in India. Bull World Health Organ 61: 689-692. (Pubitemid 13010187)
55. Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, et al. (2008) Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements. PLoS One 3.
56. Ivanov AP, Dragunsky EM (2005) ELISA as a possible alternative to the neutralization test for evaluating the immune response to poliovirus vaccines. Expert Rev Vaccines 4: 167-172. (Pubitemid 40525058)
57. Simhon A, Lifshitz A, Abed Y, Lasch EE, Schoub B, et al. (1990) How to predict the immune status of poliovirus vaccinees? A comparison of virus neutralization at a very low serum dilution versus ELISA in a cohort of infants. Int J Epidemiol 19: 164-168. (Pubitemid 20126852)
58. Swain SL, McKinstry KK, Strutt TM (2012) Expanding roles for CD4(+) T cells in immunity to viruses. Nat Rev Immunol 12: 136-148.
59. Hird TR, Grassly NC (2012) Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 8: e1002599.
60. Resik S, Tejeda A, Lago PM, Diaz M, Carmenates A, et al. (2010) Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 201: 1344-1352.
61. Mohammed AJ, AlAwaidy S, Bawikar S, Kurup PJ, Elamir E, et al. (2010) Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 362: 2351-2359.
62. Moriniere BJ, van Loon FP, Rhodes PH, Klein-Zabban ML, Frank-Senat B, et al. (1993) Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet 341: 1545-1550. (Pubitemid 23170458)
63. Herremans TMPT, Reimerink JHJ, Buisman AM, Kimman TG, Koopmans MPG (1999) Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol 162: 5011-5018. (Pubitemid 29314910)